MCM
CLDX icon

McRae Capital Management’s Celldex Therapeutics CLDX Stock Holding History

McRae Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-777
Closed -$41K – 106
2016
Q4 		$41K Sell
777
-246
-24% -$14K 0.02% 99
2016
Q3 		$62K Sell
1,023
-67
-6% -$4.17K 0.03% 99
2016
Q2 		$72K Buy
1,090
+215
+25% +$13.6K 0.03% 98
2016
Q1 		$50K Buy
+875
New +$98.5K 0.02% 95

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

McRae Capital Management's CLDX Position: Q1 2017 in Review

McRae Capital Management sold out of Celldex Therapeutics (CLDX) in Q1 2017, closing a stake of 777 shares — an estimated $41K sold.

McRae Capital Management first reported a position in CLDX in Q1 2016 and held it in 4 quarters. The position peaked at $72K in Q2 2016. 134 funds tracked by Wall St. Rank hold CLDX as of Q1 2017.

  • McRae Capital Management reported no remaining Celldex Therapeutics position as of Q1 2017 after selling out during the quarter.
  • McRae Capital Management sold 777 Celldex Therapeutics shares in Q1 2017, an estimated $41K.
  • McRae Capital Management first reported a position in Celldex Therapeutics in Q1 2016 and held it in 4 quarters.
  • McRae Capital Management's Celldex Therapeutics position peaked at $72K in Q2 2016.
  • 134 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2017.

Based on McRae Capital Management's 13F filing for Q1 2017, filed 10 May 2017.